• Type:
  • Category:

BRAIN Biotech AG Financial Results Q1 2022 / 23 | Revenue and Cash Improved with CFO

Share

BRAIN Biotech AG Q1 2022/23: Key Takeaways

Revenue Growth in BRAIN Biotech AG

BRAIN Biotech AG, a leading provider of biologization solutions for industries, has reported strong revenue growth in both segments, contributing to a total group revenue increase of 35% and an organic increase of 19% in the first quarter the fiscal year 2022/23.

 

BioIndustrial and BioScience Segment Performance

The BioIndustrial segment saw revenue growth of 43.5%, and the BioScience segment’s revenue increased by 10.5% on an organic basis. The company’s cash on hand also improved by €2.4 million to €10.8 million, including the proceeds from the disposal of L.A. Schmitt GmbH.

 

Profitability and Investments

Despite higher personnel and project investments, BRAIN Biotech’s adjusted EBITDA remained profitable.

 

Quarterly Highlights and Collaborations

Important events for the quarter included MP Beteiligungs-GmbH expanding its shareholding to approximately 45% and the company reaching project milestones in its collaboration with rare sugars expert Bonumose.

 

CFO Insights into Fiscal Year Prospects

Michael Schneiders, CFO, expressed optimism for the rest of the fiscal year, noting the company’s solid growth as a foundation for handling inflationary costs.

Chapters
  • Business Highlights 3M 22/23
  • Financial Highlights 3M FY 2022/23
  • Cash & Cash Flow
  • General Risk Factor Update
  • Our Targets
Resources
Presentation
BRAIN Biotech Video Hub
Podcast
Host
michaelschneiders - BRAIN Biotech AG Financial Results Q1 2022 / 23 | Revenue and Cash Improved with CFO -%sitename%

Michael Schneiders
CFO | BRAIN Biotech AG​

Linkedin Envelope
Share
T&C:

This publication is for informational purposes only and should not be considered investment advice. By using this website, you agree to the terms and conditions outlined in the legal pages at www.seat11a.com/legal/

Continuing the Journey: More Presentations

Discover Additional Elevator Pitches

Release Date

February 28, 2023

Duration

05:45

Director

Reviews for BRAIN Biotech AG Financial Results Q1 2022 / 23 | Revenue and Cash Improved with CFO
There are currently no reviews for BRAIN Biotech AG Financial Results Q1 2022 / 23 | Revenue and Cash Improved with CFO
COMPANIES:

Germany:

Austria:

Estonia:

Finland:

France:

Italy:

Poland:

Spain:

PRESENTATIONS:
INDUSTRIES:
Linkedin Twitter Instagram Podcast Envelope Whatsapp

(c) seat11a – Publicly Listed Companies: Elevator Pitch, Deep-Dive, Financial Results, and ESG 

Unlock the insights of top publicly listed companies with seat11a.com

Elevate your understanding with powerful Elevator Pitches, Deep-Dive Presentations, and in-depth Financial Analysis

Scroll to top